Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
FGFR2 fusion Derazantinib intrahepatic cholangiocarcinoma sensitive detail...
IDH1 R132S Dasatinib intrahepatic cholangiocarcinoma sensitive detail...
IDH1 R132S Saracatinib intrahepatic cholangiocarcinoma sensitive detail...
IDH1 R132C Saracatinib intrahepatic cholangiocarcinoma sensitive detail...
IDH1 R132C Dasatinib intrahepatic cholangiocarcinoma sensitive detail...
IDH1 R132C SRC T341I Dasatinib intrahepatic cholangiocarcinoma resistant detail...
FGFR2 F276C Infigratinib intrahepatic cholangiocarcinoma predicted - sensitive detail...
FGFR2 - SORBS1 FGFR2 K660M FGFR2 K715R Infigratinib intrahepatic cholangiocarcinoma resistant detail...
FGFR2 - SORBS1 FGFR2 K660M FGFR2 K715R Futibatinib intrahepatic cholangiocarcinoma sensitive detail...
FGFR2 - SORBS1 Infigratinib intrahepatic cholangiocarcinoma sensitive detail...
FGFR2 - SORBS1 FGFR2 V565F Futibatinib intrahepatic cholangiocarcinoma resistant detail...
FGFR2 - ZMYM4 Infigratinib intrahepatic cholangiocarcinoma sensitive detail...
FGFR2 - ZMYM4 FGFR2 N550H FGFR2 N550K FGFR2 V565F FGFR2 E566A FGFR2 K660M Infigratinib intrahepatic cholangiocarcinoma resistant detail...
FGFR2 - ZMYM4 FGFR2 N550H FGFR2 N550K FGFR2 V565F FGFR2 E566A FGFR2 K660M Futibatinib intrahepatic cholangiocarcinoma sensitive detail...
FGFR2 - ZMYM4 FGFR2 V563L Futibatinib intrahepatic cholangiocarcinoma resistant detail...
FGFR2 - INA Debio 1347 intrahepatic cholangiocarcinoma sensitive detail...
FGFR2 - INA FGFR2 M538I FGFR2 N550H FGFR2 N550T FGFR2 L618V FGFR2 H683L Debio 1347 intrahepatic cholangiocarcinoma resistant detail...
FGFR2 - INA FGFR2 M538I FGFR2 N550H FGFR2 N550T FGFR2 L618V FGFR2 H683L Futibatinib intrahepatic cholangiocarcinoma sensitive detail...
FGFR2 - INA FGFR2 V565L FGFR2 E566A Futibatinib intrahepatic cholangiocarcinoma resistant detail...
FGFR2 - NRAP Infigratinib intrahepatic cholangiocarcinoma sensitive detail...
FGFR2 - NRAP Futibatinib intrahepatic cholangiocarcinoma sensitive detail...
FGFR2 - NRAP FGFR2 N550K Futibatinib intrahepatic cholangiocarcinoma resistant detail...
FGFR2 - KIAA1217 Futibatinib intrahepatic cholangiocarcinoma sensitive detail...
FGFR2 fusion FGFR2 M538I Infigratinib intrahepatic cholangiocarcinoma decreased response detail...
FGFR2 fusion FGFR2 N550H Infigratinib intrahepatic cholangiocarcinoma decreased response detail...
FGFR2 fusion FGFR2 E566A Infigratinib intrahepatic cholangiocarcinoma decreased response detail...
FGFR2 fusion FGFR2 H683L Infigratinib intrahepatic cholangiocarcinoma decreased response detail...
FGFR2 fusion FGFR2 N550K Infigratinib intrahepatic cholangiocarcinoma resistant detail...
FGFR2 fusion FGFR2 V565F Infigratinib intrahepatic cholangiocarcinoma resistant detail...
FGFR2 fusion FGFR2 L618V Infigratinib intrahepatic cholangiocarcinoma resistant detail...
FGFR2 fusion FGFR2 K660M Infigratinib intrahepatic cholangiocarcinoma resistant detail...
FGFR2 fusion FGFR2 K715R Infigratinib intrahepatic cholangiocarcinoma sensitive detail...
FGFR2 fusion FGFR2 K715R Debio 1347 intrahepatic cholangiocarcinoma sensitive detail...
FGFR2 fusion FGFR2 M538I Debio 1347 intrahepatic cholangiocarcinoma decreased response detail...
FGFR2 fusion FGFR2 N550H Debio 1347 intrahepatic cholangiocarcinoma decreased response detail...
FGFR2 fusion FGFR2 V565F Debio 1347 intrahepatic cholangiocarcinoma decreased response detail...
FGFR2 fusion FGFR2 E566A Debio 1347 intrahepatic cholangiocarcinoma decreased response detail...
FGFR2 fusion FGFR2 H683L Debio 1347 intrahepatic cholangiocarcinoma decreased response detail...
FGFR2 fusion FGFR2 N550K Debio 1347 intrahepatic cholangiocarcinoma resistant detail...
FGFR2 fusion FGFR2 L618V Debio 1347 intrahepatic cholangiocarcinoma resistant detail...
FGFR2 fusion FGFR2 K660M Debio 1347 intrahepatic cholangiocarcinoma resistant detail...
FGFR2 fusion FGFR2 V565F Futibatinib intrahepatic cholangiocarcinoma resistant detail...
FGFR2 fusion FGFR2 K715R Futibatinib intrahepatic cholangiocarcinoma sensitive detail...
FGFR2 fusion FGFR2 M538I Futibatinib intrahepatic cholangiocarcinoma sensitive detail...
FGFR2 fusion FGFR2 N550H Futibatinib intrahepatic cholangiocarcinoma sensitive detail...
FGFR2 fusion FGFR2 N550K Futibatinib intrahepatic cholangiocarcinoma sensitive detail...
FGFR2 fusion FGFR2 E566A Futibatinib intrahepatic cholangiocarcinoma sensitive detail...
FGFR2 fusion FGFR2 L618V Futibatinib intrahepatic cholangiocarcinoma sensitive detail...
FGFR2 fusion FGFR2 K660M Futibatinib intrahepatic cholangiocarcinoma sensitive detail...
FGFR2 fusion FGFR2 H683L Futibatinib intrahepatic cholangiocarcinoma sensitive detail...
FGFR2 - BICC1 Derazantinib intrahepatic cholangiocarcinoma predicted - sensitive detail...
FGFR2 - KIAA1217 Derazantinib intrahepatic cholangiocarcinoma predicted - sensitive detail...
FGFR2 - SH3GLB1 Derazantinib intrahepatic cholangiocarcinoma predicted - sensitive detail...
FGFR2 - CCAR2 Derazantinib intrahepatic cholangiocarcinoma predicted - sensitive detail...
FGFR2 - AHCYL1 Derazantinib intrahepatic cholangiocarcinoma predicted - sensitive detail...
FGFR2 - BFSP2 Derazantinib intrahepatic cholangiocarcinoma predicted - sensitive detail...
FGFR2 - CCDC6 Derazantinib intrahepatic cholangiocarcinoma predicted - sensitive detail...
FGFR2 - TACC2 Derazantinib intrahepatic cholangiocarcinoma predicted - sensitive detail...
FGFR2 - CIT Derazantinib intrahepatic cholangiocarcinoma predicted - resistant detail...
FGFR2 - TACC1 Derazantinib intrahepatic cholangiocarcinoma predicted - resistant detail...
FGFR2 rearrange Pemigatinib intrahepatic cholangiocarcinoma sensitive detail...
FGFR2 fusion Pemigatinib intrahepatic cholangiocarcinoma sensitive detail...
FGFR2 H167_N173del Debio 1347 intrahepatic cholangiocarcinoma predicted - sensitive detail...
FGFR2 H167_N173del FGFR2 L617F Debio 1347 intrahepatic cholangiocarcinoma predicted - resistant detail...
RET fusion BLU-667 intrahepatic cholangiocarcinoma predicted - sensitive detail...
FGFR2 Y376C AZD4547 intrahepatic cholangiocarcinoma predicted - sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT02428855 Phase II Dasatinib Phase II Trial of Dasatinib in Patients With Isocitrate Dehydrogenase (IDH)-Mutant Advanced Intrahepatic Cholangiocarcinoma Completed
NCT02632305 Phase II Cisplatin + Gemcitabine + Nab-paclitaxel A Study to See the Effects That a New Combination of the Three Drugs, Nab-paclitaxel, Gemcitabine, and Cisplatin Has on Biliary Tract Cancer (AX-CSARC) Recruiting
NCT02834013 Phase 0 Ipilimumab + Nivolumab Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting
NCT02834780 Phase I H3B-6527 Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma Recruiting
NCT03230318 Phase II Derazantinib Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma (FIDES-01) Recruiting
NCT03684811 Phase Ib/II Cisplatin + Gemcitabine + Olutasidenib Azacitidine + Olutasidenib Olutasidenib Nivolumab + Olutasidenib A Study of FT 2102 in Participants With Advanced Solid Tumors and Gliomas With an IDH1 Mutation Active, not recruiting
NCT04003636 Phase III Cisplatin + Gemcitabine Cisplatin + Gemcitabine + Pembrolizumab Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966) (KEYNOTE-966) Recruiting
NCT04057365 Phase II DKN-01 + Nivolumab A Single Arm Phase II Study of the Combination of DKN-01 and Nivolumab in Previously Treated Patients With Advanced Biliary Tract Cancer (BTC) Recruiting
NCT04093362 Phase III Futibatinib Cisplatin + Gemcitabine Futibatinib Vs Gemcitabine-Cisplatin Chemotherapy as 1st-Line Treatment of Patients With Advanced Cholangiocarcinoma (CCA) Harboring FGFR2 Gene Rearrangements (FOENIX-CCA3) Not yet recruiting
NCT04175912 Phase II Carboplatin + MLN4924 + Paclitaxel MLN4924 Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver Recruiting
NCT04203160 Phase Ib/II Cisplatin + Gemcitabine Cisplatin + CPI-613 + Gemcitabine Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04) Recruiting
NCT04301778 Phase II Durvalumab + SNDX-6352 Durvalumab in Combination With a CSF-1R Inhibitor (SNDX-6532) Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma Not yet recruiting
NCT04306367 Phase II Olaparib + Pembrolizumab Study of Pembrolizumab and Olaparib in Bile Duct Cancer Recruiting
NCT04466891 Phase II ZW25 A Study of ZW25 (Zanidatamab) in Subjects With Advanced or Metastatic HER2-Amplified Biliary Tract Cancers Recruiting